Compare AOUT & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AOUT | CRDL |
|---|---|---|
| Founded | 2020 | 2017 |
| Country | United States | Canada |
| Employees | N/A | 18 |
| Industry | Ordnance And Accessories | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 121.7M | 132.6M |
| IPO Year | 2020 | 2017 |
| Metric | AOUT | CRDL |
|---|---|---|
| Price | $9.76 | $1.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $12.50 | $8.50 |
| AVG Volume (30 Days) | 32.1K | ★ 381.7K |
| Earning Date | 03-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 98.94 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $222,322,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.06 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10.55 | N/A |
| 52 Week Low | $6.26 | $0.88 |
| 52 Week High | $13.46 | $1.71 |
| Indicator | AOUT | CRDL |
|---|---|---|
| Relative Strength Index (RSI) | 52.29 | 32.82 |
| Support Level | $8.09 | $0.94 |
| Resistance Level | $9.84 | $1.18 |
| Average True Range (ATR) | 0.50 | 0.06 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 63.24 | 8.77 |
American Outdoor Brands Inc is engaged in the business of providing outdoor products and accessories for hunting, fishing, camping, shooting, and personal security and defense products. The company designs and produces products and accessories, including shooting supplies, rest, vaults, and other related accessories; premium sportsman knives and tools for fishing and hunting; land management tools for hunting preparedness; harvesting products for post-hunt or post-fishing activities; electro-optical devices, including hunting optics, firearm aiming devices, flashlights, and laser grips; reloading, gunsmithing, and firearm cleaning supplies; and survival, camping, and emergency preparedness products.
Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.